Provention Bio Reports Third Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/27/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Provention Bio Inc. (PRVB) Tops Q3 EPS by 5c
November 5, 2019 5:00 PM ESTProvention Bio Inc. (NASDAQ: PRVB) reported Q3 EPS of ($0.24), $0.05 better than the analyst estimate of ($0.29).
"The PRV-031 program continues to build momentum, with positive developments on the regulatory front that strengthen our confidence in the path forward for the prevention or delay of the onset of clinical type 1 diabetes (T1D) in at-risk individuals," stated Ashleigh Palmer, CEO, Provention Bio. "Recent... More
